GET DAILY SIGNALSBioventus (BVS) Q3 2026 Earnings: Revenue Shortfall but EPS Beat and Margin Gains
Key Takeaways
- Third-quarter 2026 revenue rose 3% to $142.4 million but missed the roughly $149.5 million consensus estimate.
- Adjusted earnings per share (EPS) came in at $0.17, topping analyst expectations and up 13% from $0.15 a year earlier.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $28 million, with the margin expanding 70 basis points to 20%.
- Full-year 2026 revenue guidance was lowered to $590–$595 million, while adjusted EPS guidance of $0.75–$0.79 was reaffirmed.
- Pain Treatments led growth at 6%, while softness in Bone Graft Substitutes (BGS) weighed on Surgical Solutions.
- For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover AI-driven trading ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
BVS is a global medical device company focused on active healing and musculoskeletal therapies. Its third-quarter 2026 report, released on November 2, 2026 for the period ended September 26, 2026, offered investors an important checkpoint on whether the company's growth drivers—peripheral nerve stimulation (PNS), platelet-rich plasma (PRP), Ultrasonics, and international expansion—could offset headwinds in its bone graft business. The results also landed against the backdrop of an ongoing strategic review, prompted by an unsolicited acquisition proposal and multiple expressions of interest. Because management updated its full-year outlook, this report carries meaningful weight for how analysts and shareholders assess the company's near-term trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
BVS reported third-quarter 2026 net sales of $142.4 million, a 3% increase from $138.7 million in the prior-year period but below the roughly $149.5 million consensus estimate. Adjusted earnings per diluted share came in at $0.17, topping analyst expectations and advancing 13% from $0.15 a year earlier. On a GAAP (Generally Accepted Accounting Principles) basis, net income attributable to Bioventus was $6.0 million, or $0.08 per diluted share, compared with $3.2 million, or $0.05 per diluted share, in the year-ago quarter.
Adjusted EBITDA rose to $28 million, with the adjusted EBITDA margin expanding 70 basis points to 20%. By segment, Pain Treatments revenue grew 6% to $71 million, Surgical Solutions rose 1% to $51 million, and Restorative Therapies declined 3% to $21 million. International revenue increased 16% to $18 million. Management attributed the top-line shortfall primarily to weaker-than-expected Bone Graft Substitutes (BGS) within Surgical Solutions.
The company lowered its full-year 2026 net sales guidance to a range of $590 million to $595 million, down from $600 million to $610 million previously, while reaffirming its full-year adjusted EPS outlook of $0.75 to $0.79.
Market Reaction and Investor Sentiment
Shares of BVS fell sharply in after-hours trading following the release, with reported declines ranging from roughly 11% to 19% as investors weighed the revenue miss and the reduction to full-year sales guidance against the earnings beat. The stock had risen substantially year-to-date heading into the report, which likely amplified the negative reaction to the softer top line. Sentiment was tempered by management's characterization of the BGS softness as transitory, as well as its decision to reaffirm the full-year adjusted EPS outlook, but the sales shortfall and lower revenue forecast remained the dominant near-term concern.
Forward Outlook and Key Factors to Monitor
Management expects a sequential acceleration in revenue growth in the fourth quarter, citing mid-single-digit growth expectations and early positive trends in October following corrective actions in the BGS business. Investors will be watching whether the bone graft segment stabilizes and whether the company's growth drivers continue to gain traction.
On the growth front, PNS and PRP are progressing, with PRP disposable kit revenue exceeding capital placements for the first time and trial-to-permanent conversion rates running ahead of plan. Ultrasonics delivered strong double-digit growth, and international revenue is projected to grow more than 20% in the fourth quarter. These are key indicators of whether the company can broaden its revenue base beyond its legacy portfolio.
Balance sheet momentum is another area to monitor. BVS generated $21 million in cash from operations during the quarter, repaid an additional $19 million of debt, and reduced net debt below $200 million, with management targeting a net leverage ratio below 1.5 times by year-end. Finally, the ongoing strategic alternatives review—initiated by unsolicited acquisition interest—remains an important wildcard that could shape the company's future direction.
AI Tools in My Research Workflow
In my analysis of names like BVS, I frequently rely on Tickeron’s AI Screener to scan for comparable medical device stocks and evaluate technical and fundamental signals side by side. It streamlines the process of identifying peers with similar growth profiles or volatility patterns, which helps put quarterly results into broader context without spending hours on manual data pulls. This approach has proven especially useful when tracking sector trends and potential trade setups.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BVS in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 21, 2026
BVS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 37 of the 42 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BVS moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 29 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 57 cases where BVS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BVS as a result. In 73 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for BVS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
BVS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The 10-day moving average for BVS crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where BVS advanced for three days, in 221 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 166 of 207 cases where BVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.934) is normal, around the industry mean (4.204). P/E Ratio (16.235) is within average values for comparable stocks, (1.723). Projected Growth (PEG Ratio) (1.529) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.583) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What are Accounts Receivable?
What is an Accounting Period?
Cisco Systems (CSCO) Q3 2025 Earnings Preview: What to Expect and the Role of Tickeron’s AI Double Agent Trading
AI Agents for Crypto Markets
Penny Stocks in a Housing Recession: How a 9.7‑Month Supply Shock Could Reshape Small‑Cap Trades in 2026
General Information
Industry MedicalNursingServices
Advertisement